First report on echinocandin resistant Polish Candida isolates

Acta Biochim Pol. 2019 Sep 12;66(3):361-364. doi: 10.18388/abp.2019_2826.

Abstract

Purpose: Candida spp. are ranked as one of the four major causative agents of fungal infections. The number of infections caused by Candida species resistant to fluconazole, which is applied as the first line drug in candidiasis treatment, increases every year. In such cases the application of echinocandin is necessary. Echinocandin susceptibility testing has become a routine laboratory practice in many countries due to the increasing frequency of clinical failures during treatment with these drugs.

Methods: We performed anidulafungin, micafungin and caspofungin susceptibility testing according to the microdilution broth method on 240 Candida isolates collected in Polish hospitals.

Results: We identified 12 isolates resistant to all echinocandins within 240 examined isolates. Moreover, 6 of the examined samples were identified as rare Candida species and among them we observed very high echinocandin MIC values.

Conclusion: Our research proves that in Poland there is a problem of echinocandin resistance. Moreover, we identified two species of Candida which are rare causative agents of human infections, and there was no reported incidence of such infections in Poland until now.

MeSH terms

  • Anidulafungin / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Candida / drug effects*
  • Candida / isolation & purification
  • Candidiasis / drug therapy*
  • Candidiasis / epidemiology*
  • Candidiasis / microbiology
  • Caspofungin / therapeutic use
  • Drug Resistance, Fungal / drug effects*
  • Echinocandins / adverse effects
  • Echinocandins / therapeutic use*
  • Humans
  • Micafungin / therapeutic use
  • Microbial Sensitivity Tests
  • Poland / epidemiology

Substances

  • Antifungal Agents
  • Echinocandins
  • Anidulafungin
  • Caspofungin
  • Micafungin